GL1X · GenesisL1 explorer

MolNFT v1 · #176887 · protein

Crystal structure of human indoleamine 2,3-dioxygenagse 1 (HIDO1) complexed with (1R,2S)-2-(((6-bromo-1H-indazol-4-YL)AMINO)METHYL) cyclohexan-1-ol (23)

7E0S · Indoleamine 2,3-dioxygenase 1: “Crystal structure of human indoleamine 2,3-dioxygenagse 1 (HIDO1) complexed with…”. X-ray diffraction, 2 ligands (HEM, HU6), 6 pockets (best druggability 0.89). MolNFT v1 #176887 on GenesisL1: 3D…

PDB
7E0S
Type
protein
Length
746 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Indoleamine 2,3-dioxygenase 1
EC
1.13.11.52
UniProt
P14902
Ligands
HEM, HU6
Pockets
6 · best druggability 0.89

Structure

x-ray diffraction · 1 distinct chain · 59% helix, 4% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BIndoleamine 2,3-dioxygenase 1 (EC 1.13.11.52)protein37359% helix, 4% strandP14902

Ligands and binding sites

  • HEM · Protoporphyrin IX containing Fe · ligand · 2 copies · chains A, B
  • HU6 · (1~{R},2~{S})-2-[[(6-bromanyl-1~{H}-indazol-4-yl) amino]methyl]cyclohexan-1-ol · ligand · 2 copies · chains A, B
  • ACY · Acetic acid · additive · chains B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

6 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110150.890.91143HEM, HU6
21020.630.8918empty
3510.480.8616empty
4820.390.7821empty
51040.370.7419empty

Interfaces

1 interface between chains.

  • A–B · 625 Ų buried · 9 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 1 disulfide (disulfide).

Compared structures

  • 7E0S · Crystal Structure of Human Indoleamine 2,3-dioxygenagse 1 (hIDO1) Complexed with… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.